4.4 Review

Identification of lymphoma predictors in patients with primary Sjogren's syndrome: a systematic literature review and meta-analysis

Journal

RHEUMATOLOGY INTERNATIONAL
Volume 35, Issue 1, Pages 17-26

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s00296-014-3051-x

Keywords

Sjogren syndrome; Lymphoma; Clinical markers; Immunological markers

Categories

Funding

  1. Spanish Rheumatology Foundation (FER) through ROCHE pharmaceuticals
  2. European Union [316265, FP7/REGPOT-2012-2013.1]

Ask authors/readers for more resources

To identify risk and predictors of lymphoma or lymphoproliferative disease in patients with primary Sjogren syndrome. Articles were identified through a comprehensive search strategy in Medline, Embase and Cochrane CENTRAL. Studies had to investigate primary Sjogren syndrome patients, 18 years of age or older, with the goal of examining potential clinical, immunological and hematological risk factors for lymphoma or lymphoproliferative disease. The quality of the studies was graded using the Oxford Levels of Evidence Scale. Whenever possible, the authors created evidence tables and performed meta-analysis. Of 900 studies identified, 18 were selected for inclusion. These studies provided data from over 15,000 patients (90 % female) for analysis. Lymphadenopathy, parotid enlargement, palpable purpura, low C4 serum levels and cryoglobulins were the most consistent non-HodgkinA ' s lymphoma/lymphoproliferative disease predictors. Additionally, some of the studies identified splenomegaly, low C3 serum levels, lymphopenia and neutropenia as significant prognostic factors. The detection of germinal center-like lesions in primary Sjogren Syndrome diagnostic salivary biopsies was also proposed as highly predictive of non-HodgkinA ' s lymphoma. In contrast, anemia, anti-Ro, anti-La, antinuclear antibodies, rheumatoid factor, male gender and hypergammaglobulinemia were not associated with lymphoma or lymphoproliferative disease. Patients with primary Sjogren syndrome have an increased risk of lymphoma or lymphoproliferative disease compared to the general population. Ascertaining relevant and reliable predictors in this patient population would greatly facilitate the identification of patients at elevated risk for closer monitoring in the context of limited resources.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available